HR 6502 · 112th Congress 2011โ€“2013, ended

Life-Threatening Diseases Compassion through Combination Therapy Act of 2012

Latest action · Sep 26, 2012 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedSep 21, 2012
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Life-Threatening Diseases Compassion through Combination Therapy Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act to authorize the Secretary of Health and Human Services (HHS) to designate a combination of drugs as a significant drug combination if such combination: (1) includes two or more drugs or biological products that, when used in combination, offer the potential to significantly advance treatment for a serious or life-threatening disease and, in combination, meet the criteria for co-development of drug combinations in Food and Drug Administration (FDA) guidance; and (2) includes at least two drugs that are not approved.

Requires the Secretary to develop, publish, and revise annually a list of combinations of two or more drugs designated as significant drug combinations.

Extends the market exclusivity for a drug by six months if it is designated as a significant drug combination before it is approved as a new drug.

Requires the Secretary to review and take action on a drug in a significant drug combination designated under this Act within six months after receiving an application for approval of a new drug application or licensure of a biosimilar biological product.

Requires the Secretary, at the request of the sponsor of a drug, to expedite development and review for designated drug combinations.

Requires the Secretary to establish an interagency task force to encourage the co-development of drugs in significant drug combinations. Requires the task force to develop, revise in response to public comments, and update annually a list of types of drug combinations it recommends that the Secretary designate as significant drug combinations.

Directs the Secretary to study the impact of the extension of market exclusivity under this Act.

Cosponsors 2

Members who signed on, in the order they did. All signed on Sep 21, 2012.

SeatCosponsorSigned on
D-NYCarolyn B. MaloneyOriginalSep 21, 2012
D-CTRosa L. DeLauroOriginalSep 21, 2012

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Sep 21, 2012
Health Subcommittee
Referred Sep 26, 2012

Actions 3

Everything that happened, newest first.

  1. Sep 26, 2012Referred to the Subcommittee on Health.
  2. Sep 21, 2012Introduced in House
  3. Sep 21, 2012Referred to the House Committee on Energy and Commerce.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article 1, Section 8, To regulate Commerce with foreign Nations, and among the several States, and with the Indian Tribes; Congress has the authority under this section to regulate commerce and FDA products.

The sponsor’s statement, as printed in the page H6277.

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend title V of the Federal Food, Drug, and Cosmetic Act to provide for extensions of marketing exclusivity periods for drugs in certain combinations of such drugs, and for other purposes.
Short Titles as Introduced
Life-Threatening Diseases Compassion through Combination Therapy Act of 2012

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Sep 21, 2012Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.